As mentioned above, SGLT2 was overexpressed in malignant cancers, including pancreatic and prostate adenocarcinomas [9], lung cancer [27], and breast cancer [28], and the overexpression of SGLT2 significantly promoted the proliferation, migration, and invasion abilities in malignant cancers [12, 13]. Here, SLC5A2 is linked to prostate adenocarcinoma.